H. Lundbeck A/S is to pay $200 million upfront to Otsuka Pharmaceutical Co Ltd of Japan as part of an alliance that will give it access to two late clinical stage CNS compounds including a new formulation of the antidepressant, aripiprazole.
H. Lundbeck A/S posted a 9.8% increase in revenue to DKK 3.97 billion (€0.53 billion) in the third quarter of 2011 compared with the year-earlier period but its operating profit fell by 22% to DKK 660 million due to an exceptional charge.
Paion AG reduced its loss in the first nine months of 2011 but said that difficult conditions on the capital markets and restrained investment by the pharmaceutical industry had delayed the planned out-licensing of two products.
Merck Serono is set to pay Ablynx NV €20 million upfront as part of a new agreement to co-discover and co-develop antibody-derived therapeutic proteins against two targets in osteoarthritis. This is an expansion of an existing partnership.
Oxford BioMedica Plc has entered into a research and development collaboration with the Mayo Clinic in the US to develop a gene therapy for the treatment of chronic glaucoma. It is the company’s second partnership in the area of eye disease.
Bavarian Nordic A/S has announced receipt of a $25 million milestone payment from the US government in connection with the scaling up of production of its smallpox vaccine, Imvamune, for delivery to the US national strategic stockpile.
Curetis AG of Germany has raised €9.6 million in additional Series A funding in order to support the development and registration of its molecular diagnostic technologies for the detection of infectious disease.
Prosensa BV is set to receive a credit of up to €5 million from the Dutch government, payable on the achievement of milestones, to support the development of preclinical compounds for Myotonic Dystrophy type 1 using RNA modulation technology.
Silence Therapeutics Plc has entered into an agreement with Mirna Therapeutics Inc of Austin, Texas to apply its delivery technologies to the US company’s candidate microRNA-based therapeutics for cancer. Financial details weren’t disclosed.
Syntaxin Ltd, which is a 2005 spin-out of the UK Health Protection Agency, has entered into an agreement with Ipsen SA of France to discover and develop therapies in the field of botulinum toxins in a deal potentially valued at more than $100 million.